Targeted alpha therapy for solid tumors: biological rationale, clinical advances, and future perspectives
Frontiers in Oncology · 02.11.2026 · 16
DOI: 10.3389/fonc.2026.2007300 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 02.11.2026. Verfasst von Qimin Li und 4 weiteren Autor:innen. Die Arbeit nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Targeted alpha therapy (TAT) delivers high-linear-energy-transfer radiation over a few cell diameters and is being explored for resistant and microscopic solid-tumor disease. This targeted narrative review evaluates alpha-emitting platforms and clinical evidence by tumor type and development stage, with a focused literature update through 12 October 2026. Unlike broader radiochemistry-centered reviews, we place approved, randomized, early-phase, observational, and preclinical findings in separate evidence tiers. Radium-223 dichloride has randomized survival evidence in symptomatic bone-metastatic castration-resistant prostate cancer, whereas molecularly targeted actinium-225, lead-212, astatine-211, and thorium-227 agents remain investigational in the indications discussed. Updated examples include the 2026 ACTION-1 actinium-225-DOTATATE dosimetry substudy, the 2026 first-in-human astatine-211-MABG study, 2025 lead-212-DOTAMTATE phase II disclosures, and a negative 2025 mesothelin-targeted thorium-227 study. Quantitative outcomes are reported with their study design and limitations rather than interpreted as indirect head-to-head comparisons. Major barriers include isotope supply, incomplete daughter retention, salivary, marrow, and kidney toxicity, spatially heterogeneous target uptake, and uncertainty in patient-specific microdosimetry. We propose practical, imaging-led selection and a priority-ranked translational roadmap.
Zitieren
APA
Li, Q., Xie, J., Chen, F., Li, L., & Yang, C. (2026). Targeted alpha therapy for solid tumors: biological rationale, clinical advances, and future perspectives. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.2007300
Vancouver
Li Q, Xie J, Chen F, Li L, Yang C. Targeted alpha therapy for solid tumors: biological rationale, clinical advances, and future perspectives. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.2007300
BibTeX
@article{Li2026,
author = {Li, Qimin and Xie, Jian and Chen, Fei and Li, Laixiang and Yang, Chuansheng},
title = {Targeted alpha therapy for solid tumors: biological rationale, clinical advances, and future perspectives},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.2007300}
}
EUVIMED